Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,464 total articles

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs, a biotech company focused on inflammatory and immune-mediated diseases, announced plans to start a Phase 2 clinical trial in 2026 to evaluate its drug candidate SL-325 for moderate to severe hidradenitis suppurativa (HS). The company also appointed Dr. Shoba Ravichandran as Senior Vice President of Clinical Development to lead this p…

Fervo Energy Declares Commercial Operation at Cape Station Ahead of Schedule, Leading the Race for Next-Generation Geothermal Energy

Fervo Energy Declares Commercial Operation at Cape Station Ahead of Schedule, Leading the Race for Next-Generation Geothermal Energy

Fervo Energy announced that its first GeoBlock at Cape Station in Utah achieved commercial operation ahead of schedule, generating 33 MW of net power and starting revenue under its power purchase agreement. This milestone establishes Fervo's leadership in enhanced geothermal systems (EGS) and signals the viability of reliable, carbon-free power pro…

What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?

What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?

Medifast's Trilivy metabolic health system identifies five often overlooked signs of poor metabolic health and offers a structured framework, incorporating its MetaVantage Reset Formula and coaching support, to improve metabolic outcomes. A clinical trial showed 14% reduction in visceral fat and 98% lean mass retention over 16 weeks, supporting the…

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader targeting inflammatory pathways linked to atherosclerotic cardiovascular disease (ASCVD). In obese subjects with elevated cardiovascular risk, MRT-8102 demonstrated robust NEK7 degradation and significant reduction…

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Kyntra Bio announces the appointment of Andrew E. Singer, MBA, a seasoned biotechnology finance and strategy executive, to its Board of Directors and Audit Committee. The move aims to leverage Mr. Singer's extensive expertise to advance the company's rare disease and oncology pipeline and support strategic priorities. Concurrently, long-serving boa…

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Generate Biomedicines and Roswell Park Comprehensive Cancer Center have initiated a Phase 1 clinical trial for GB-5267, an investigational AI-designed IL-18 armored CAR T-cell therapy aimed at treating platinum-resistant ovarian cancer by targeting the MUC16 antigen. The approach focuses on overcoming solid tumor microenvironment challenges without…

USA Rare Earth Completes CEO Transition

USA Rare Earth Completes CEO Transition

USA Rare Earth, a Nasdaq-listed rare earth and critical minerals company, has completed its CEO succession with Thras Moraitis stepping into the role. Moraitis aims to integrate the company's diverse operations across mining, processing, and magnet manufacturing in the US, Brazil, and UK. The company is structured into three business units to enhan…

Anfield Energy Receives Positive Colorado DRMS Decision Completing State Review of JD-8 Uranium-Vanadium Mine

Anfield Energy Receives Positive Colorado DRMS Decision Completing State Review of JD-8 Uranium-Vanadium Mine

Anfield Energy received approval from the Colorado Division of Reclamation, Mining and Safety on the reclamation permit application for its JD-8 uranium and vanadium mine, a key asset in Anfield's Monogram Mesa Mine Complex. The decision clears state-level permitting, with federal approvals underway, targeting a restart of production by mid-2027. T…

Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base

Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base

Origin Agritech Limited announced the sale of its 70.5% equity interest in its Xinjiang Originbo seed production base to Hunan Xindaxin Limited for approximately US$15 million. Concurrently, a five-year lease-back agreement ensures operational continuity at the production facility, preserving seed supply stability. The proceeds will be deployed to …

Manifests Ireland Grows Customs Operations from 20,000 to 2 Million Annual Declarations with Descartes Customs Compliance Solution

Manifests Ireland Grows Customs Operations from 20,000 to 2 Million Annual Declarations with Descartes Customs Compliance Solution

Descartes Systems Group's customs compliance platform, Descartes Thyme™, has powered Manifests Ireland's growth from 20,000 to 2 million annual customs declarations since Brexit. This long-term partnership has enabled Manifests Ireland to automate complex customs processes, maintain compliance, and expand operations into new European markets with e…

Oaktree Asset-Backed Finance Fund Closes at $2 Billion

Oaktree Asset-Backed Finance Fund Closes at $2 Billion

Brookfield announced the final close of Oaktree's Asset-Backed Finance Fund (ABF I) at $2 billion, hitting its fundraising target with commitments from global institutional investors. The fund will provide flexible capital across sectors such as equipment leasing, transportation, consumer finance, real estate, and infrastructure. This close complem…